Brief: Grand Pharmaceutical Says SIR-Spheres Y-90 Microsphere Injection US HCC Study Reaches Clinical Endpoint
13/04/2026 14:18
April 13 (Reuters) - Grand Pharmaceutical Group Ltd 0512.HK: SIR-SPHERES Y-90 MICROSPHERE INJECTION US HCC STUDY REACHES CLINICAL ENDPOINT Further company coverage: 0512.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement